{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:13:58Z","timestamp":1792840438615,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Idiopathic refractory membranous nephropathy (IRMN) is a subset of nephrotic syndrome with a high risk of progression to end-stage renal disease, yet treatment options remain limited. Obinutuzumab, a humanized type II anti-CD20 antibody, induces efficient CD20+ cell depletion, leading to favorable immunological and proteinuria responses in IRMN. This study sought to assess the effectiveness and safety of obinutuzumab for treating IRMN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 31 patients with IRMN were enrolled and received obinutuzumab therapy. They were followed for 12 months. The primary endpoint was the remission rate (complete or partial remission). Secondary outcomes included changes in proteinuria, serum albumin, serum creatinine, anti-PLA2R antibody levels, CD20\/CD19 cell counts, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 12 months, the overall remission rate was 80%, with 16% achieving complete remission and 64% achieving partial remission. The median time to remission was 4.5 months (IQR 2.0\u20137.0 months). The immunological remission rates at 3, 6, 9, and 12 months were 70, 83, 90, and 93%, respectively. Regarding anti-PLA2R antibodies, 80% of patients showed a rapid decline within the first 3 months (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001), with 64% achieving a &amp;gt; 50% reduction from baseline by month 3. At the last follow-up, all patients had achieved seroconversion to anti-PLA2R antibody negativity. Adverse events included infusion-related reactions such as fever, hypotension, tachycardia, and flushing. No deaths occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Obinutuzumab effectively induces remission in patients with IRMN and demonstrates a tolerable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1704970","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:22:20Z","timestamp":1770787340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Obinutuzumab in the treatment of idiopathic refractory membranous nephropathy: an observational case series"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiangling","family":"Zhao","sequence":"first","affiliation":[{"name":"Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Chang","sequence":"additional","affiliation":[{"name":"Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duqun","family":"Chen","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manshu","family":"Yu","sequence":"additional","affiliation":[{"name":"Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Mao","sequence":"additional","affiliation":[{"name":"Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxia","family":"Juan","sequence":"additional","affiliation":[{"name":"Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature.","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"B2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2215\/cjn.04321007","article-title":"Idiopathic membranous nephropathy: diagnosis and treatment.","volume":"3","author":"Fervenza","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/cjn.11761116","article-title":"Primary membranous nephropathy.","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e42774","DOI":"10.1097\/md.0000000000042774","article-title":"Association between immune cell subtypes and membranous nephropathy: a bidirectional mendelian randomization study.","volume":"104","author":"Yu","year":"2025","journal-title":"Medicine (Baltimore)."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3390\/genes14071343","article-title":"The role of PLA2R in primary membranous nephropathy: do we still need a kidney biopsy?","volume":"14","author":"McDonnell","year":"2023","journal-title":"Genes (Basel)."},{"key":"B6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e104936","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis.","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2215\/cjn.07210810","article-title":"Anti-phospholipase a2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2478\/rjim-2018-0044","article-title":"Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.","volume":"57","author":"Provatopoulou","year":"2019","journal-title":"Rom J Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1681\/asn.2005010028","article-title":"Management of membranous nephropathy: when and what for treatment.","volume":"16","author":"Cattran","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases.","volume":"100","year":"2021","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/08916934.2017.1385775","article-title":"Higher frequencies of circulating ICOS(+), Il-21(+) T follicular helper cells and plasma cells in patients with new-onset membranous nephropathy.","volume":"50","author":"Zhang","year":"2017","journal-title":"Autoimmunity."},{"key":"B13","doi-asserted-by":"publisher","first-page":"588.e","DOI":"10.1053\/j.ajkd.2023.10.013","article-title":"Anti-phospholipase A2 receptor 1 and anti-cysteine rich antibodies, domain recognition and rituximab efficacy in membranous nephropathy: a prospective cohort study.","volume":"83","author":"Ruggenenti","year":"2024","journal-title":"Am J Kidney Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.","volume":"115","author":"Beers","year":"2010","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","article-title":"Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics.","volume":"5","author":"Golay","year":"2013","journal-title":"MAbs."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/asn.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy.","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1053\/j.ajkd.2021.04.014","article-title":"Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: a case series with extended follow up.","volume":"78","author":"Zonozi","year":"2021","journal-title":"Am J Kidney Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases.","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ekir.2022.12.011","article-title":"Novel treatments paradigms: membranous nephropathy.","volume":"8","author":"Rojas-Rivera","year":"2023","journal-title":"Kidney Int Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.25259\/ijn_391_2024","article-title":"Obinutuzumab as a promising treatment for membranous nephropathy.","volume":"35","author":"Meena","year":"2025","journal-title":"Indian J Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1016\/j.xphs.2019.07.013","article-title":"PKPD assessment of the anti-CD20 antibody obinutuzumab in cynomolgus monkey is feasible despite marked anti-drug antibody response in this species.","volume":"108","author":"Grimm","year":"2019","journal-title":"J Pharm Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"sfaf026","DOI":"10.1093\/ckj\/sfaf026","article-title":"Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.","volume":"18","author":"Su","year":"2025","journal-title":"Clin Kidney J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.ekir.2024.05.004","article-title":"Obinutuzumab as initial or second-line therapy in patients with primary membranous nephropathy.","volume":"9","author":"Su","year":"2024","journal-title":"Kidney Int Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/ndt\/gfad225","article-title":"Membranous nephropathy treatment standard.","volume":"39","author":"Radhakrishnan","year":"2024","journal-title":"Nephrol Dial Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/asn.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial.","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ekir.2019.12.006","article-title":"Rituximab in patients with phospholipase A2 receptor-associated membranous nephropathy and severe CKD.","volume":"5","author":"Hanset","year":"2020","journal-title":"Kidney Int Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by Elisa predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1044782","DOI":"10.3389\/fendo.2023.1044782","article-title":"Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: a single-centre experience.","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11255-020-02633-5","article-title":"Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis.","volume":"53","author":"Huang","year":"2021","journal-title":"Int Urol Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1156470","DOI":"10.3389\/fimmu.2023.1156470","article-title":"Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/asn.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy.","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/asn.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up.","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA(2)R-associated membranous nephropathy with obinutuzumab: a report of 3 cases.","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy.","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.nephro.2021.10.002","article-title":"Evaluation of efficacy of rituximab for membranous nephropathy: a systematic review and meta-analysis of 11 studies.","volume":"18","author":"Ou","year":"2022","journal-title":"Nephrol Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000437236","article-title":"Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy.","volume":"42","author":"Timmermans","year":"2015","journal-title":"Am J Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1053\/j.ajkd.2025.08.013","article-title":"What\u2019s new in membranous nephropathy and how to incorporate new antigen discoveries into clinical practice?","volume":"87","author":"Zand","year":"2026","journal-title":"Am J Kidney Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"sfaf115","DOI":"10.1093\/ckj\/sfaf115","article-title":"The importance of identifying new and putative target antigens associated with membranous nephropathy: evidence from a Sardinian cohort.","volume":"18","author":"Lepori","year":"2025","journal-title":"Clin Kidney J."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1704970\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:22:20Z","timestamp":1770787340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1704970\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":38,"alternative-id":["10.3389\/fmed.2026.1704970"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1704970","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1704970"}}